{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:04:49Z","timestamp":1695575089427},"reference-count":32,"publisher":"The Japanese Society for Medical Mycology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Mycology Journal"],"published-print":{"date-parts":[[2016]]},"DOI":"10.3314\/mmj.57.j13","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T17:09:12Z","timestamp":1456765752000},"page":"J13-J18","source":"Crossref","is-referenced-by-count":4,"title":["Antifungal Activity of Luliconazole Nail Solution on &lt;I&gt;in vitro&lt;\/I&gt; and &lt;I&gt;in vivo&lt;\/I&gt; Onychomycosis Model"],"prefix":"10.3314","volume":"57","author":[{"given":"Tsuyoshi","family":"Shimamura","sequence":"first","affiliation":[{"name":"R&D Laboratories, POLA PHARMA INC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nami","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"R&D Laboratories, POLA PHARMA INC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Kubota","sequence":"additional","affiliation":[{"name":"R&D Laboratories, POLA PHARMA INC."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1842","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, Sullivan S, Daniel R, Krusinski P, Fleckman P, Rich P, Odom R, Aly R, Pariser D, Zaiac M, Rebell G, Lesher J, Gerlach B, Ponce-De-Leon GF, Ghannoum A, Warner J, Isham N, Elewski B: A large-scale North American study of fungal isolates from nails: the frequency of onycho-mycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 43 : 641-648, 2000.","DOI":"10.1067\/mjd.2000.107754"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ogasawara Y: Prevalence and patient&rsquo;s consciousness of tinea pedis and onychomycosis. Jpn J Med Mycol 44 : 253-260, 2003.","DOI":"10.3314\/jjmm.44.253"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Haneke E, Roseeuw D: The scope of onychomycosis: epidemiology and clinical features. Int J Dermatol 38 (Suppl 2) : 7-12, 1999.","DOI":"10.1046\/j.1365-4362.1999.00015.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Pires CAA, Cruz NFSd, Lobato AM, Sousa POd, Carneiro FRO, Mendes AMD : Clinical, epidemiological, and therapeutic profile of dermatophytosis. An Bras Dermatol 89 : 259-264, 2014.","DOI":"10.1590\/abd1806-4841.20142569"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Panackal AA, Halpern EF, Watson AJ: Cutaneous fungal infections in the United States : Analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995-2004. Int J Dermatol 48 : 704-712, 2009.","DOI":"10.1111\/j.1365-4632.2009.04025.x"},{"key":"6","unstructured":"7) Ghannoum MA, Mukherjee PK, Warshaw EM, Evans S, Korman NJ, Tavakkol A: Molecular analysis of dermatophytes suggests spread of infection among household members. Cutis 91 : 237-245, 2013."},{"key":"7","unstructured":"8) Daniel RC : Onychomycosis : burden of disease and the role of topical antifungal treatment. J Drugs Dermatol 12 : 1263-1266, 2013."},{"key":"8","unstructured":"9) Elewski B, Tavakkol A : Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease : a proven reality. Ther Clin Risk Manag 1 : 299-306, 2005."},{"key":"9","doi-asserted-by":"crossref","unstructured":"10) Gupta AK, Daigle D, Paquet M : Therapies for Onychomycosis: A Systematic Review and Network Meta-Analysis of Mycological Cure. J Am Podiatr Med Assoc 105 : 357-366, 2015.","DOI":"10.7547\/13-110.1"},{"key":"10","unstructured":"11) Gupta AK, Cvetkovic D, Abramovits W, Vincent KD : LUZU (luliconazole) 1% cream. Skinmed 12 : 90-93, 2014."},{"key":"11","doi-asserted-by":"crossref","unstructured":"12) Uchida K, Nishiyama Y, Yamaguchi H : <I>In vitro<\/I> antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother 10 : 216-219, 2004.","DOI":"10.1007\/s10156-004-0327-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13) Koga H, Tsuji Y, Inoue K, Kanai K, Majima T, Kasai T, Uchida K, Yamaguchi H : <I>In vitro<\/I> antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother 12 : 163-165, 2006.","DOI":"10.1007\/s10156-006-0440-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14) Koga H, Nanjoh Y, Makimura K, Tsuboi R : <I>In vitro<\/I> antifungal activities of luliconazole, a new topical imidazole. Med Mycol 47 : 640-647, 2009.","DOI":"10.1080\/13693780802541518"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15) Shimamura T, Kubota N, Nagasaka S, Suzuki T, Mukai H, Shibuya K: Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents. Antimicrob Agents Chemother 55 : 3150-3155, 2011.","DOI":"10.1128\/AAC.00399-11"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16) Koga H, Nanjoh Y, Kaneda H, Yamaguchi H, Tsuboi R : Short-term therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis. Antimicrob Agents Chemother 56 : 3138-3143, 2012.","DOI":"10.1128\/AAC.05255-11"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17) Yoshida T, Uchida K, Yamaguchi H : An ATP bioluminescence assay applicable to rapid fluconazole susceptibility testing of dermatophytes. Microbiol Immunol 41 : 377-386, 1997.","DOI":"10.1111\/j.1348-0421.1997.tb01868.x"},{"key":"17","unstructured":"18) Memarzadeh B, Fasasi K, Turner RB, Lim ST, Najafi A, Brown MB : <I>In vitro<\/I> evaluation of stable derivatives of the Chlorotaurines on infected human nail model as potent antifungal agents for the treatment of onychomycosis, P1056, 47th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, 2009."},{"key":"18","unstructured":"19) Del Rosso JQ : The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol 7 : 10-18, 2014."},{"key":"19","doi-asserted-by":"crossref","unstructured":"20) Alley MR, Baker SJ, Beutner KR, Plattner J : Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs 16 : 157-167, 2007.","DOI":"10.1517\/13543784.16.2.157"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21) Ghannoum M, Isham N : Fungal nail infections (onychomycosis): a never-ending story? PLoS Pathog 5 : e1004105, 2014.","DOI":"10.1371\/journal.ppat.1004105"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22) Azambuja CV, Pimmel LA, Klafke GB, Xavier MO : Onychomycosis : clinical, mycological and <I>in vitro<\/I> susceptibility testing of isolates of Trichophyton rubrum. An Bras Dermatol 89 : 581-586, 2014.","DOI":"10.1590\/abd1806-4841.20142630"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23) Tatsumi Y, Yokoo M, Arika T, Yamaguchi H : <I>In vitro<\/I> antifungal activity of KP-103, a noveltriazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis andcutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother 45 : 1493-1499, 2001.","DOI":"10.1128\/AAC.45.5.1493-1499.2001"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24) Baker SJ, Zhang YK, Akama T, Lau A, Zhou H, Hernandez V, Mao W, Alley MR, Sanders V, Plattner JJ : Discovery of a new boron-containing antifungal agent, 5-fluoro-1, 3-dihydro-1-hydroxy-2, 1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 49 : 4447-4450, 2006.","DOI":"10.1021\/jm0603724"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25) Palliyil B, Lebo DB, Patel PR : A preformulation strategy for the selection of penetration enhancers for a transungual formulation. AAPS PharmSciTech 14 : 682-691, 2013.","DOI":"10.1208\/s12249-013-9954-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26) Subissi A, Monti D, Togni G, Mailland F : Ciclopirox : recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 70 : 2133- 2152, 2010.","DOI":"10.2165\/11538110-000000000-00000"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27) Hui X, Baker SJ, Wester RC, Barbadillo S, Cashmore AK, Sanders V, Hold KM, Akama T, Zhang YK, Plattner JJ, Maibach HI : <I>In Vitro<\/I> penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci 96 : 2622-2631, 2007.","DOI":"10.1002\/jps.20901"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28) Tanriverdi ST, &Ouml;zer &Ouml; : Novel topical formulations of Terbinafine-HCl for treatment of onychomycosis. Eur J Pharm Sci 48 : 628-636, 2013.","DOI":"10.1016\/j.ejps.2012.12.014"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29) Osborne CS, Leitner I, Favre B, Ryder NS : Antifungal drug response in an <I>in vitro<\/I> model of dermatophyte nail infection. Med Mycol 42 : 159-163, 2004.","DOI":"10.1080\/13693780310001656803"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30) Nowrozi H, Nazeri G, Adimi P, Bashashati M, Emami M : Comparison of the activities of four antifungal agents in an <I>in vitro<\/I> model of dermatophyte nail infection. Indian J Dermatol 53 : 125-128, 2008.","DOI":"10.4103\/0019-5154.43216"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31) Lusiana, Reichl S, Muller-Goymann CC : Infected nail plate model made of human hair keratin for evaluating the efficacy of different topical antifungal formulations against Trichophyton rubrum <I>in vitro<\/I>. Eur J Pharm Biopharm 84 : 599-605, 2013.","DOI":"10.1016\/j.ejpb.2013.01.015"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32) Schaller M, Borelli C, Berger U, Walker B, Schmidt S, Weindl G, J&auml;ckel A : Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an <I>in vitro<\/I> model of dermatophyte nail infection. Med Mycol 47 : 753-758, 2009.","DOI":"10.3109\/13693780802577892"},{"key":"32","unstructured":"33) Tomiyama S, Nagasaka S, Nishida Y, Shiraishi K, Shimamura T, Masui S, Majima T. <I>In<\/I> A novel mycological method for evaluation of antifungal agents in the stratum corneum of guinea pigs, pp. 133, 16th Congress of the International Society for Human and Animal Mycology, Paris, 2006."}],"container-title":["Medical Mycology Journal"],"original-title":["&lt;I&gt;In vitro&lt;\/I&gt;\u304a\u3088\u3073&lt;I&gt;in vivo&lt;\/I&gt;\u722a\u767d\u766c\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u30eb\u30ea\u30b3\u30ca\u30be\u30fc\u30eb\u722a\u5916\u7528\u6db2\u306e\u6297\u771f\u83cc\u52b9\u679c"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/57\/1\/57_J13\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T23:53:50Z","timestamp":1567641230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/57\/1\/57_J13\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.3314\/mmj.57.j13","relation":{},"ISSN":["2185-6486","2186-165X"],"issn-type":[{"value":"2185-6486","type":"print"},{"value":"2186-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}